@media only screen and (min-width: 768px) and (max-width: 1023px) {

	/*global*/
	#header .indication-selector .header-dropdown ul li.init:after {
		/*right: 14px;*/
	}
	.indent {
		text-indent: -6px;
	}
	#header .indication-selector .header-dropdown {
		top: 34px;
	}
	.fullnavigation .navbar-default .navbar-nav>li.olaparib-dose-management,
	.fullnavigation .navbar-default .navbar-nav>li.olaparib-patient-support {
		/*top: -59px;*/
	}
	/*global*/
	/*home*/
	.landing-hero {
		padding: 1%;
	}
	/*.home .recommend_content.container-center img {
		width: 16%;
	}*/
	.fullheader .logos .logo {
		padding: 15px 10px;
	}
	.moa-page .moa-bottom-content.new {
		margin-top: 0px;
	}
    .home .home_eyebrow{
    	/* padding: 1% 2%; */
    	padding: 1.1% 2%;
    	line-height: 22px;
    }
	/*home*/
	/*moa*/
	.moa-page p.footnote.new {
		padding-top: 5%;
	}
	/*moa*/
	/*treatment paradigm*/
	.treatment-paradigm .asco-metastatic {
    	padding: 54px 20px;
	}
	.treatment_paradigm .recommend_based {
		padding-left: 11%;
	}
	.treatment_paradigm .recommend_bullet {
		padding-left: 15%;
	}
	.treatment_paradigm .recommend img {
		padding-top: 4%;
	}
    .treatment_paradigm .flex_container .flex_content{
        margin: 5%;
    }
	/*treatment paradigm*/
	/*efficacy*/
	.efficacy .study_design_description {
		margin-top: 0px;
	}
	.efficacy .flex_container {
		margin-left: 2%;
        text-align:center;
	}
	.kaplan {
		padding-left: 20px !important;
		padding-right: 20px !important;
	}
	.orr .study_design {
		padding-top: 2%;
		padding-bottom: 1%;
	}
	.efficacy .flex_one .flex_content, .flex_two .flex_content, .flex_three .flex_content {
   	 margin: 1% 3% 4% 4%;
	}
	.efficacy .flex_one .flex_content{
   	 margin-top: 7%;
	}
    .efficacy .polo_left_align {
        padding-left: 20px;
    }
	/*efficacy*/
	/*brca*/
	.brca_content_bg .flex_content {
		padding-right: 16%;
	}
    .BRCA-Testing .blue_bg {
        width:98%

    }

	.BRCA-Testing .flex_content ul {
        margin-left: -4%;
    }
    .brca_flex_two .blue_bg img {
        margin-left: 1.5%;
        margin-top:4px;
    }
.brca_flex_three .blue_bg img {
    margin-top: 2px!important;
    padding-left: 3.75%;
}
.brca_flex_one .blue_bg img {
    padding-left: 2%;
    margin-top: 4.5px;
    width: 80px !important;
}
.safety-tolerability .home_footnote:nth-child(1) {
    margin-top:12px;
}
    .BRCA-Testing .brca_content_bg{
        width:83%;
    }
    .BRCA-Testing .blue_bg{
        width:98%;
        background-size:108%;
    }
    .BRCA-Testing .flex_container_brca{
        padding-left:20px;
    }
    .BRCA-Testing #brcafoot{
        padding-left:10px;
    }
.home_footnote.second-foot.container-center {
       margin-top:0;
}
.effi_footnote.kaplan-meier {padding-left:22px;}
.effi_footnote:nth-child(1) {padding-left:25px;}
.fullnavigation .navbar-default .navbar-nav>li.olaparib-dose-management a {padding: 4px 20px;}
	/*brca*/
/*result page*/
    .search-results .common-headline h1 {
        padding-left: 3%;
    }
/*result page*/
}

@media only screen and (min-width: 768px) and (max-width: 1024px) and (orientation: landscape) {
    	.BRCA-Testing .recommend_platinum {
        width:93%;
    }


}